These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1901298)

  • 41. Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer.
    Yamashita J; Ogawa M; Yamashita S; Nakashima Y; Saishoji T; Nomura K; Inada K; Kawano I
    Br J Cancer; 1993 Sep; 68(3):524-9. PubMed ID: 8394731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of plasminogen activator by estrogen in a human breast cancer cell line (MCF-7).
    Butler WB; Kirkland WL; Jorgensen TL
    Biochem Biophys Res Commun; 1979 Oct; 90(4):1328-34. PubMed ID: 518601
    [No Abstract]   [Full Text] [Related]  

  • 43. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gonadotropin surge-induced up-regulation of the plasminogen activators (tissue plasminogen activator and urokinase plasminogen activator) and the urokinase plasminogen activator receptor within bovine periovulatory follicular and luteal tissue.
    Dow MP; Bakke LJ; Cassar CA; Peters MW; Pursley JR; Smith GW
    Biol Reprod; 2002 May; 66(5):1413-21. PubMed ID: 11967205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
    Harbeck N; Kates RE; Schmitt M
    J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
    Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
    Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study.
    Horvatić Herceg G; Herceg D; Kralik M; Bence-Zigman Z; Tomić-Brzac H; Kulić A
    Wien Klin Wochenschr; 2006 Oct; 118(19-20):601-9. PubMed ID: 17136335
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
    Knoop A; Andreasen PA; Andersen JA; Hansen S; Laenkholm AV; Simonsen AC; Andersen J; Overgaard J; Rose C
    Br J Cancer; 1998 Mar; 77(6):932-40. PubMed ID: 9528837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
    Harbeck N; Thomssen C
    Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estrogen regulation of human breast cancer cell line MCF-7 tissue plasminogen activator.
    Dickerman HW; Martinez HL; Seeger JI; Kumar SA
    Endocrinology; 1989 Jul; 125(1):492-500. PubMed ID: 2500332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation of plasminogen activator in rat endometrial stromal cells: the role of prostaglandin E2.
    Zhang X; Shu MA; Ross HE; Kennedy TG
    Biol Reprod; 1996 May; 54(5):1046-51. PubMed ID: 8722625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential.
    Lockwood CJ; Krikun G; Aigner S; Schatz F
    J Clin Endocrinol Metab; 1996 Jan; 81(1):107-12. PubMed ID: 8550736
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.
    Sappino AP; Busso N; Belin D; Vassalli JD
    Cancer Res; 1987 Aug; 47(15):4043-6. PubMed ID: 2440556
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
    Duffy MJ; O'Grady P; Devaney D; O'Siorain L; Fennelly JJ; Lijnen HJ
    Cancer; 1988 Aug; 62(3):531-3. PubMed ID: 3134120
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of transforming growth factor-beta on plasminogen activator production of cultured human uveal melanoma cells.
    Park SS; Li L; Korn TS; Mitra MM; Niederkorn JY
    Curr Eye Res; 1996 Jul; 15(7):755-63. PubMed ID: 8670784
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.
    Pedersen AN; Christensen IJ; Stephens RW; Briand P; Mouridsen HT; Danø K; Brünner N
    Cancer Res; 2000 Dec; 60(24):6927-34. PubMed ID: 11156392
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
    Harbeck N; Schmitt M; Kates RE; Kiechle M; Zemzoum I; Jänicke F; Thomssen C
    Clin Breast Cancer; 2002 Aug; 3(3):196-200. PubMed ID: 12196277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
    Xing RH; Mazar A; Henkin J; Rabbani SA
    Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
    Dublin E; Hanby A; Patel NK; Liebman R; Barnes D
    Am J Pathol; 2000 Oct; 157(4):1219-27. PubMed ID: 11021826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.